Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare Conference

   Orexigen Therapeutics to Present at the Jefferies 2013 Global Healthcare
                                  Conference

PR Newswire

SAN DIEGO, May 30, 2013

SAN DIEGO, May 30, 2013 /PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq:
OREX) today announced that management will present a company overview at the
Jefferies 2013 Global Healthcare Conference in New York. The presentation is
scheduled for Monday, June 3^rd at 12:30 p.m. Eastern Time. To listen to the
live webcast or a replay of the presentation, please visit the Investor
Relations section of the Company's Web site at www.orexigen.com. A replay will
be available for 14 days after the event.

About Orexigen® Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the
treatment of obesity. The Company's lead product candidate is Contrave®, which
has completed Phase 3 clinical trials and for which a New Drug Application has
been submitted and reviewed by the FDA. The Company has also reached agreement
with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the
Contrave cardiovascular outcomes trial. The Company's other product candidate,
Empatic™, has completed Phase 2 clinical trials. Further information about the
Company can be found at www.orexigen.com.

Orexigen Contact:                                     Media Contact:
McDavid Stilwell                                      Denise Powell
VP, Corporate Communications and Business Development BrewLife
(858) 875-8629                                        (510) 703-9491

SOURCE Orexigen Therapeutics, Inc.

Website: http://www.orexigen.com